Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-03-29
2011-03-29
Bowman, Amy (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C514S04400A
Reexamination Certificate
active
07915400
ABSTRACT:
The present invention concerns methods and reagents useful in modulating hepatitis C virus (HCV) gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against hepatitis C virus (HCV) gene expression and/or activity. The small nucleic acid molecules are useful in the treatment and diagnosis of HCV infection, liver failure, hepatocellular carcinoma, cirrhosis and any other disease or condition that responds to modulation of HCV expression or activity.
REFERENCES:
patent: 5814620 (1998-09-01), Robinson et al.
patent: 5998203 (1999-12-01), Matulic-Adamic et al.
patent: 5998206 (1999-12-01), Cowsert
patent: 6346398 (2002-02-01), Pavco et al.
patent: 2004/0053875 (2004-03-01), Kreutzer et al.
patent: 2005/0020521 (2005-01-01), Rana
patent: 2005/0058982 (2005-03-01), Han et al.
patent: 2005/0080246 (2005-04-01), Allerson et al.
patent: 2006/0134189 (2006-06-01), MacLachlan et al.
patent: 2359180 (2000-03-01), None
patent: WO90/14090 (1990-11-01), None
patent: WO94/01550 (1994-01-01), None
patent: WO99/29350 (1999-06-01), None
patent: WO99/32619 (1999-07-01), None
patent: WO99/49029 (1999-09-01), None
patent: WO00/44895 (2000-08-01), None
patent: WO01/36646 (2001-05-01), None
patent: WO01/68836 (2001-09-01), None
patent: WO01/75164 (2001-10-01), None
patent: WO01/96584 (2002-03-01), None
patent: WO02/22636 (2002-03-01), None
patent: WO02/44321 (2002-06-01), None
patent: WO03/016572 (2003-02-01), None
patent: WO03/064626 (2003-08-01), None
Elbashir et al., Functional anatomy of siRNAs for mediating efficienct RNAi inDrosophila melanogasterembryo lysate, 2001, The EMBO Journal, vol. 20, No. 23, pp. 6877-6888.
Anderson et al. “Bispecific Short Hairpin siRNA Constructs Targeted to CD4, CXCR4, and CCR5 Confer HIV-1 Resistance,” Oligonucleotides 13(5):303-312 (2003).
Elbashir et al. “Analysis of Gene Function in Somatic Mammalian Cells Using Small Interfering RNAs,” Methods 26 (2):199-213 (2002).
Elbashir et al. “Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells,” Nature 411(6836):494-498 (2001).
Elbashir et al. “Functional Anatomy of siRNAs for Mediating Efficient RNAi inDrosophila melanogasterEmbryo Lysate,” EMBO J. 20(23):6877-6888 (2001).
Elbashir et al. “RNA Interference is Mediated by 21- and 22-Nucleotide RNAs,” Genes Dev. 15(2):188-200 (2001).
Fire et al. “Potent and Specific Genetic Interference by Double-Stranded RNA inCaenorhabditis elegans,” Nature 391:806-811 (1998).
Futami et al. “Induction of Apoptosis in HeLa Cells with siRNA Expression Vector Targeted Against BcI-2,” Nucleic Acids Research Supplement 2:251-252 (2002).
International Search Report mailed on Mar. 31, 2005 for PCT/US04/16390, 2 pages.
International Search Report mailed on Oct. 17, 2003 for PCT/US03/05028, 2 pages.
International Search Report mailed on Oct. 17, 2003 for PCT/US03/05346, 1 page.
Leirdal et al. “Gene Silencing in Mammalian Cells by Preformed Small RNA Duplexes,” Biochemical and Biophysical Research Communications 295:744-748 (2002).
Lin et al. “A Novel mRNA-cDNA Interference Phenomenon for Silencing Bcl-2 Expression in Human LNCaP Cells,” Biochemical and Biophysical Research Communications 281:639-644 (2001).
Tuschl et al. “Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy,” Molecular Interventions 295(3):158-167 (2002).
Tuschl et al. “Targeted mRNA Degradation by Double-Stranded RNA In Vitro,” Genes and Development 13 (24):3191-3197 (1999).
Office Action mailed on Feb. 4, 2008 for U.S. Appl. No. 10/444,853, 37 pages.
Office Action mailed on Jul. 1, 2008 for U.S. Appl. No. 11/499,520, 13 pages.
Office Action mailed on Oct. 8, 2008 for U.S. Appl. No. 11/499,529, 34 pages.
Office Action mailed on Nov. 14, 2008 for U.S. Appl. No. 11/502,875, 14 pages.
Office Action mailed on Apr. 8, 2009 for U.S. Appl. No. 11/502,876, 31 pages.
Office Action mailed on Jan. 26, 2009 for U.S. Appl. No. 11/676,124, 15 pages.
Office Action mailed on Feb. 3, 2009 for U.S. Appl. No. 10/693,059, 7 pages.
Office Action mailed on Jul. 2, 2008 for U.S. Appl. No. 10/757,803, 26 pages.
Office Action mailed on Apr. 16, 2009 for U.S. Appl. No. 12/105,010, 24 pages.
McCaffrey, et al., Nature, vol. 418, pp. 38-39 (2002).
Randall, et al., PNAS, vol. 100(1), pp. 235-240 (2003).
Bass, et al., Nature, vol. 411, pp. 428-429 (2001).
Kapadia, et al., PNAS, vol. 100(4), pp. 2014-2018 (2003).
Kennerdell, Nature Biotech., vol. 18(8), pp. 896-898 (2000).
Tavernarakis, et al., Nature Genetics, vol. 24(2), pp. 180-183 (2000).
Parrish, et al., Molecular Cell 6, pp. 1077-1087 (2000).
Wu, et al., Croatian Med. Journal, vol. 42(4), pp. 463-466 (2001).
Hammond, et al., Nature Rev. Genet., vol. 2(2), pp. 110-119 (2001).
Caplen, Expert Opin. Biol. Ther., vol. 3(4), pp. 575-586 (2003).
Kurreck, et al., Nucleic Acid Res., vol. 30(9), pp. 1911-1918 (2002).
Bertrand, et al., Biochemical and Biophysical Research Communications, vol. 296, pp. 1000-1004 (2002).
Braasch, et al., Biochemistry, vol. 41(14), pp. 4503-4570 (2002).
Olie, et al., Biochemica et Biophysica Acta, vol. 1576, pp. 101-109 (2002).
Office Action mailed Dec. 18, 2007 in U.S. Appl. No. 10/667,271, 43 pgs.
Request for Continued Examination with 1.114(c) Amendment filed Oct. 18, 2007 in U.S. Appl. No. 10/667,271, 27 pgs.
Final Office Action mailed Apr. 18, 2007 in U.S. Appl. No. 10/667,271, 8 pgs.
1.111 Amendment filed Feb. 28, 2007 in U.S. Appl. No. 10/667,271, 12 pgs.
Office Action mailed Aug. 28, 2006 in U.S. Appl. No. 10/667,271, 13 pgs.
Beigelman Leonid
McSwiggen James
Bowman Amy
Ginkel Laura M.
Merck Sharp & Dohme Corp.
Muthard David A.
LandOfFree
RNA interference mediated inhibition of hepatitis C virus... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with RNA interference mediated inhibition of hepatitis C virus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RNA interference mediated inhibition of hepatitis C virus... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2739276